Literature DB >> 15582834

Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels.

Meir Bialer1, Roy E Twyman, H Steve White.   

Abstract

OBJECTIVE: Although there are several animal models of epilepsy, the extrapolation of antiepileptic drug (AEDs) performance to epileptic patients from anticonvulsant activity results in animals is not straightforward. Consequently, the aim of this work was to perform a correlation analysis between therapeutic daily doses (D) and average steady-state plasma concentrations (Css,av) of AEDs and their activity in common anticonvulsant animal models.
METHODS: AED activity in anticonvulsant animal models was expressed as maximal electroshock seizure (MES) test ED50 values in mice and rats and ED50 values in audiogenic seizure-susceptible mice (AGS ED50). Data were examined, by use of linear and logarithmic approaches, for an association between Css,av (mg/L or micromol/L) and D (mg or mmol) for each AED in epileptic patients as the dependent variable (Y) and its MES ED50 in mice and rats and AGS ED50 in mice (mg/kg or micromol/kg) as the independent variable (X).
RESULTS: Linear correlation analyses between Css,av (mg/L) and ED50 (mg/kg) for 11 AEDs gave the following correlation coefficients (R2): 0.68 (mice, MES); 0.73 (rat, MES); 0.64 (AGS). Switching the units from milligrams to micromoles improved the correlation significantly and gave the following R2 values: 0.88 (mice, MES); 0.90 (rat, MES); 0.76 (AGS). The linear correlation between Css,av and ED50 was better than that between D and ED50.
CONCLUSIONS: The results of this analysis suggest that the relationship between Css,av and ED50 is useful in predicting target concentration ranges in humans. The Y intercepts of the Css,av-versus-ED50 and D-versus- ED50 plots were similar in all three animal models and ranged between 12 and 17 mg/L and between 570 and 890 mg, respectively, indicating that for all AEDs analyzed except valproic acid and ethosuximide, the therapeutic plasma concentration is in the range 10-20 mg/L.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15582834     DOI: 10.1016/j.yebeh.2004.08.021

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  23 in total

Review 1.  Key factors in the discovery and development of new antiepileptic drugs.

Authors:  Meir Bialer; H Steve White
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 2.  Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.

Authors:  Melissa Barker-Haliski; H Steve White
Journal:  Neuropharmacology       Date:  2019-08-27       Impact factor: 5.250

3.  Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy.

Authors:  Melissa L Barker-Haliski; Taylor D Heck; E Jill Dahle; Fabiola Vanegas; Timothy H Pruess; Karen S Wilcox; H Steve White
Journal:  Epilepsia       Date:  2016-10-14       Impact factor: 5.864

4.  The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant.

Authors:  Nichole Coleman; Hai M Nguyen; Zhengyu Cao; Brandon M Brown; David Paul Jenkins; Dorota Zolkowska; Yi-Je Chen; Brian S Tanaka; Alan L Goldin; Michael A Rogawski; Isaac N Pessah; Heike Wulff
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

5.  The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.

Authors:  S Eyal; J G Lamb; M Smith-Yockman; B Yagen; E Fibach; Y Altschuler; H S White; M Bialer
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

6.  Evaluating an etiologically relevant platform for therapy development for temporal lobe epilepsy: effects of carbamazepine and valproic acid on acute seizures and chronic behavioral comorbidities in the Theiler's murine encephalomyelitis virus mouse model.

Authors:  Melissa L Barker-Haliski; E Jill Dahle; Taylor D Heck; Timothy H Pruess; Fabiola Vanegas; Karen S Wilcox; H Steve White
Journal:  J Pharmacol Exp Ther       Date:  2015-03-09       Impact factor: 4.030

7.  sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.

Authors:  Dan Kaufmann; Peter J West; Misty D Smith; Boris Yagen; Meir Bialer; Marshall Devor; H Steve White; K C Brennan
Journal:  Pharmacol Res       Date:  2016-11-24       Impact factor: 7.658

8.  Antiseizure drugs differentially modulate θ-burst induced long-term potentiation in C57BL/6 mice.

Authors:  Peter J West; Gerald W Saunders; Gregory J Remigio; Karen S Wilcox; H Steve White
Journal:  Epilepsia       Date:  2014-01-21       Impact factor: 5.864

Review 9.  Valproic Acid: second generation.

Authors:  Meir Bialer; Boris Yagen
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

10.  Acute cognitive impact of antiseizure drugs in naive rodents and corneal-kindled mice.

Authors:  Melissa L Barker-Haliski; Fabiola Vanegas; Matthew J Mau; Tristan K Underwood; H Steve White
Journal:  Epilepsia       Date:  2016-07-28       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.